Italy Peptide Receptor Radionuclide Therapy (PRRT) Market
There is just one licenced Italy Peptide Receptor Radionuclide Therapy (PRRT) market, and it is used to treat adult patients with foregut, midgut, and hindgut neuroendocrine tumours (GEP-NETs) that are somatostatin receptor positive. As a result, another significant factor limiting market expansion is the unavailability of various medications.
In addition, high treatment costs are anticipated to impede market expansion. For instance, the medicine Lutathera from Novartis Company costs US$ 99,900 for a complete course of treatment that includes four infusions.
Read More:
https://knackersblogger.blogspot.com/2022/09/italy-peptide-receptor-radionuclide.html
Click here for Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Press Release
